🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  2. KB105

    Krystal Biotech Netherlands B.V.

    TGM-1 Related Autosomal Recessive Congenital Ichthyosis

    phase 2 mab active

    1 trial

  3. KB105

    Krystal Biotech Netherlands B.V.

    Autosomal Recessive Ichthyosis

    phase 2 mab active

    1 trial

  4. KB304

    Krystal Biotech Netherlands B.V.

    Wrinkles in Decolletage

    phase 2 mab active

    1 trial

  5. KB707

    Krystal Biotech Netherlands B.V.

    Lung Cancer, Non-small Cell

    phase 2 mab active

    1 trial

  6. KB707

    Krystal Biotech Netherlands B.V.

    Cancer

    phase 2 mab active

    1 trial

  7. KB801

    Krystal Biotech Netherlands B.V.

    Neurotrophic Keratitis

    phase 2 mab active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., FLUOROURACIL, CAPECITABINE BIOGARAN 500 mg, comprimé pelliculé, Avastin 25 mg/ml concentrate for solution for infusion., OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE

    phase 2 small molecule active

    1 trial

  9. KN046

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Ketamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  11. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  12. L-Glutamine

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  13. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

  14. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  15. LB-100

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  16. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  17. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  18. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  19. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  20. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  22. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  23. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  24. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources